Are you struggling
to control your
blood pressure?

See if the TARGET BP I Clinical Trial is right for you

Millions of people struggle to keep their blood pressure under control, even when taking daily medications. If left untreated, high blood pressure can lead to serious health problems such as stroke, heart attack, kidney disease, and vision loss.1

If you’re struggling to control your blood pressure, you may be interested in the TARGET BP I Clinical Trial.

About the Trial


The TARGET BP I Clinical Trial is evaluating the Peregrine System™ Kit Procedure. The procedure is a minimally invasive intervention that has been shown in early studies to reduce blood pressure by calming nerves surrounding the renal (kidney) arteries.2,3,4

People with high blood pressure typically have overactive kidney nerves, and it has been shown that calming these overactive nerves may help reduce blood pressure. The Peregrine System Kit was designed to calm these overactive nerves through a one-time, minimally invasive procedure.

The Peregrine System Kit Procedure is performed through a single, small incision in the groin. A thin, flexible catheter is then guided to the artery supplying the kidney. Once positioned, the Peregrine System Catheter delivers a small amount of dehydrated alcohol to the region just outside the artery – to potentially calm these over-active nerves. After the arteries to both kidneys are treated, the Peregrine Catheter is removed, and the incision is closed.

Why Participate?

The single treatment with the Peregrine System Kit may lower your blood pressure and may reduce your need for blood pressure medications. In addition, participants in the TARGET BP I Clinical Trial may benefit from frequent careful monitoring of their blood pressure condition from a team of specialists.

If you qualify and choose to join the study, you will receive all study-related care at no cost. This includes the pre-procedural assessment, the treatment, as well as any assessments during the follow-up visits to your study doctor’s office. You may also receive reasonable reimbursement for your travel to attend these study visits.

Before you decide to participate, your local study center will review with you all potential benefits and risks, so that you can make an informed decision if the TARGET BP I Clinical Trial is right for you.

Are You Eligible?

The TARGET BP I Clinical Trial is enrolling people ages 18 - 80 years who are struggling to control their blood pressure, despite taking blood pressure reducing medication.

To see if you might qualify for the TARGET BP I Clinical Trial, and to get connected directly with your local study center to learn more, please take the questionnaire below.


  1. “Q&As on Hypertension.” World Health Organization, World Health Organization, 29 Sept. 2015, www.who.int/news-room/q-a-detail/q-as-on-hypertension.
  2. Fischell, Tim A., et al. “Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System.” JACC: Cardiovascular Interventions, vol. 9, no. 6, 2016, pp. 589–598., doi:10.1016/j.jcin.2015.11.041.
  3. Bertog, Stefan C., et al. “CRT-200.21 Alcohol-Mediated Renal Denervation to Treat Hypertension- The Peregrine Post-Market Study.” JACC: Cardiovascular Interventions, vol. 11, no. 4, 2018, doi:10.1016/j.jcin.2018.01.104.
  4. Mahfoud, Felix, et al. “Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension.” JACC: Cardiovascular Interventions, vol. 13, no. 4, Feb. 2020, pp. 471–484., doi:10.1016/j.jcin.2019.10.048.